sarcoidosis
Conditions
Interventions
The study population will be divided into two groups receiving either
Doxycycline and Azithromycin or placebo for 3 months. Both groups will contain
an equal amount of patient in which C. acnes can
Sponsors
Sint Antonius Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Biopsy proven sarcoidosis. No treatment indication for the sarcoidosis in case of treatment, started at least 12 months ago. with stable dosis and no intention of changing this treatment during this study Inflammatory activity according to FDG-PET scan SUVmax above 3 in lungs and above 5 in mediastinum/hili
Exclusion criteria
Exclusion criteria: Increased duration of QT interval (>440ms for men and >450ms for women) on ECG Hearing deficits, a possible side-effect of azithromycin use is hearing deficits, although the chance of this is very small Being pregnant or breastfeeding at time of inclusion Use of an investigational drug during the time between FDG-PET scan and screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in inflammatory activation based on blood biomarkers and FDG-PET of patients which were treated with Doxycyclin and Azithormycin compared to patients treated with placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| Measure the presence of C.acnes in biopsies Measure the activity of the signaling pathways in biopsies | — |
Countries
Netherlands
Outcome results
None listed